These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 25470720)

  • 1. Lmax and imiquimod 3.75% in daily clinical practice.
    Gupta G
    J Eur Acad Dermatol Venereol; 2015 Jan; 29 Suppl 1():15-8. PubMed ID: 25470720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lmax and imiquimod 3.75%: the new standard in AK management.
    Stockfleth E
    J Eur Acad Dermatol Venereol; 2015 Jan; 29 Suppl 1():9-14. PubMed ID: 25470719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term sustained lesion clearance from Lmax with imiquimod 3.75%, a new field-directed treatment for actinic keratosis.
    Gupta G; Stockfleth E; Peris K; Aractingi S; Alomar A; Dakovic R; Dirschka T
    J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1840-2. PubMed ID: 25174261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Imiquimod 3.75% from Lmax in Actinic Keratosis According to Fitzpatrick Skin Type.
    Alomar A; Stockfleth E; Dirschka T; Gupta G; Aractingi S; Dakovic R; Peris K
    J Drugs Dermatol; 2016 Mar; 15(3):285-9. PubMed ID: 26954313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of imiquimod 3.75% from Lmax according to the number of actinic keratosis lesions.
    Peris K; Stockfleth E; Gupta G; Aractingi S; Dakovic R; Dirschka T; Alomar A
    J Eur Acad Dermatol Venereol; 2015 Dec; 29(12):2470-3. PubMed ID: 25351284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction in lesions from Lmax: a new concept for assessing efficacy of field-directed therapy for actinic keratosis. Results with imiquimod 3.75%.
    Stockfleth E; Gupta G; Peris K; Aractingi S; Dakovic R; Alomar A
    Eur J Dermatol; 2014; 24(1):23-7. PubMed ID: 24589500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical experience of imiquimod 3.75% for actinic keratosis: results from a case series.
    Tambone S; Fargnoli MC; Capizzi R; Peris K
    G Ital Dermatol Venereol; 2018 Jun; 153(3):333-337. PubMed ID: 26439591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
    Swanson N; Smith CC; Kaur M; Goldenberg G
    J Drugs Dermatol; 2014 Feb; 13(2):166-9. PubMed ID: 24509967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3 multicenter, randomized, double-blind, placebo-controlled studies.
    Swanson N; Smith CC; Kaur M; Goldenberg G
    J Drugs Dermatol; 2013 Nov; 12(11):1278-82. PubMed ID: 24196337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imiquimod 3.75% for field-directed therapy of actinic keratosis: results of a prospective case-series study in Greece.
    Befon A; Tzanetakou V; Panagiotopoulos A; Chasapi V; Antoniou C; Stratigos AJ
    Int J Dermatol; 2019 Sep; 58(9):1040-1044. PubMed ID: 30779341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative study for the effect of photodynamic therapy, imiquimod immunotherapy and combination of both therapies on 40 lesions of actinic keratosis in Japanese patients.
    Tanaka N; Ohata C; Ishii N; Imamura K; Ueda A; Furumura M; Yasumoto S; Kawakami T; Tsuruta D; Hashimoto T
    J Dermatol; 2013 Dec; 40(12):962-7. PubMed ID: 24147543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of cross polarized light and fluorescence diagnosis for detection of sub-clinical and clinical actinic keratosis during imiquimod treatment.
    Ortonne JP; Gupta G; Ortonne N; Duteil L; Queille C; Mallefet P
    Exp Dermatol; 2010 Jul; 19(7):641-7. PubMed ID: 20201959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term clinical outcomes following treatment of actinic keratosis with imiquimod 5% cream.
    Lee PK; Harwell WB; Loven KH; Phillips TJ; Whiting DA; Andres KL; Lee JH
    Dermatol Surg; 2005 Jun; 31(6):659-64. PubMed ID: 15996416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between the clinical and histopathological classifications of actinic keratosis and the efficacy of topical imiquimod treatment.
    Yu A; Tanizaki H; Kokunai Y; Kaneda K; Sugimoto A; Otsuka T; Kurokawa T; Moriwaki S
    J Dermatol; 2018 Apr; 45(4):496-500. PubMed ID: 29265412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microarray analysis of aberrant gene expression in actinic keratosis: effect of the Toll-like receptor-7 agonist imiquimod.
    Torres A; Storey L; Anders M; Miller RL; Bulbulian BJ; Jin J; Raghavan S; Lee J; Slade HB; Birmachu W
    Br J Dermatol; 2007 Dec; 157(6):1132-47. PubMed ID: 17944981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imiquimod 3.75% cream (Zyclara) for the treatment of actinic keratoses.
    Quist SR; Gollnick HP
    Expert Opin Pharmacother; 2011 Feb; 12(3):451-61. PubMed ID: 21254950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of actinic keratoses with 5% topical imiquimod: a multicenter prospective observational study from 93 Austrian office-based dermatologists.
    Strohal R; Kerl H; Schuster L
    J Drugs Dermatol; 2012 May; 11(5):574-8. PubMed ID: 22527424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles.
    Hanke CW; Beer KR; Stockfleth E; Wu J; Rosen T; Levy S
    J Am Acad Dermatol; 2010 Apr; 62(4):573-81. PubMed ID: 20133012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of actinic keratoses with sequential use of photodynamic therapy; and imiquimod 5% cream.
    Shaffelburg M
    J Drugs Dermatol; 2009 Jan; 8(1):35-9. PubMed ID: 19180894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term clinical outcomes of imiquimod 5% cream vs. diclofenac 3% gel for actinic keratosis on the face or scalp: a pooled analysis of two randomized controlled trials.
    Gollnick H; Dirschka T; Ostendorf R; Kerl H; Kunstfeld R
    J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):82-89. PubMed ID: 31407414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.